Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics.
AMA J Ethics. 2021;23(5):E405-409. doi:
10.1001/amajethics.2021.405.
This commentary explores legal, ethical, and practical considerations for pharmacists and prescribers working together to address uncertainty in drug prescribing.
AMA J Ethics. 2021;23(6):E471-479. doi:
10.1001/amajethics.2021.471.
Furthering clinicians’ understandings of how daily practice can respond to Black patients' experiences can help restore trust and mitigate racial and ethnic health inequity.
AMA J Ethics. 2021;23(6):E480-486. doi:
10.1001/amajethics.2021.480.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Jennifer Erdrich, MD, MPH and Carlos R. Gonzales, MD
Tribal-university partnerships are fewer in education than in research, but just as important for expanding opportunity and improving health infrastructure.
AMA J Ethics. 2020;22(10):E851-855. doi:
10.1001/amajethics.2020.851.